TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs).

Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated.

Ovasave®, TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016.

Based in SophiaAntipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.